Issue Date: April 6, 2009
Sutro Advances Cell-Free Proteins
Sutro Biopharma has produced a therapeutic cytokine protein at 100-L scale using a cell-free synthesis technology. The achievement triggered a $15 million investment by venture capital investors. South San Francisco-based Sutro says it employs controlled, catalytically driven biochemical reactions to make protein-based therapeutics without the constraints of the cell wall and membrane. The firm licensed its technology from James R. Swartz, a Stanford University chemical engineering professor.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society